ALX Oncology Reports Encouraging Clinical Data of Evorpacept in Combination with Standard-of-Care in an Ongoing Phase 1/2 Clinical Trial in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma ("R/R B-NHL")

Core Insights - ALX Oncology reported promising clinical data from a Phase 1/2 trial of evorpacept combined with standard R2 treatment in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL) [1][2][3] Group 1: Clinical Trial Results - The trial enrolled 20 patients, with 18 having indolent and 2 having aggressive R/R B-NHL, all of whom had prior rituximab treatment, and 72% had prior chemoimmunotherapy [2] - Evorpacept was administered at doses of 30 mg/kg every two weeks (n=3) or 60 mg/kg every four weeks (n=17), with no dose-limiting toxicities reported [2] - The combination therapy achieved a best overall response rate (ORR) of 94% and a complete response rate (CRR) of 83% in patients with indolent R/R B-NHL, significantly higher than the historical CRR benchmark of 34% for R2 alone [1][2] Group 2: Safety and Tolerability - The treatment was well tolerated, with common adverse events including fatigue, ALT increase, anemia, and AST increase, all primarily low grade [2] - No treatment-related deaths were reported during the study [2] Group 3: Future Directions - The ongoing Phase 2 portion of the trial will evaluate the evorpacept-R2 combination in previously untreated indolent B-NHL patients [4] - ALX Oncology aims to explore novel combinations with evorpacept to enhance anti-tumor activity through the innate immune response [3][6] Group 4: Company Overview - ALX Oncology is focused on developing therapies that block the CD47 immune checkpoint pathway, with evorpacept being a next-generation CD47 blocking therapeutic [6][7] - The company has dosed over 500 subjects with evorpacept, demonstrating promising activity and a favorable tolerability profile across various malignancies [6]